1 / 13

Katherine Floyd, Lilani Kumaranayake, Haileyesus Getahun, Paul Nunn

Resources required for TB/HIV collaborative activities or What will it cost to implement TB/HIV collaborative activities?. Katherine Floyd, Lilani Kumaranayake, Haileyesus Getahun, Paul Nunn 4 th TB/HIV Working Group meeting Addis Ababa, Ethiopia September 20th 2004. Background.

donaldcox
Télécharger la présentation

Katherine Floyd, Lilani Kumaranayake, Haileyesus Getahun, Paul Nunn

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Resources required for TB/HIV collaborative activitiesorWhat will it cost to implement TB/HIV collaborative activities? Katherine Floyd, Lilani Kumaranayake, Haileyesus Getahun, Paul Nunn 4th TB/HIV Working Group meeting Addis Ababa, Ethiopia September 20th 2004

  2. Background • Cost estimates important for • advocacy and resource mobilization • to inform budgeting process • assessing affordability of activities proposed and extent to which new funding is needed • Cost estimates made for HIV/AIDS and TB control published in high profile journals • HIV/AIDS – prevention and care (Science 2001) • DOTS expansion to reach global control targets (Science 2002) • "3 by 5" initiative (Lancet 2004)

  3. Background • Existing estimates for TB/HIV are out-of-date • from 2001 • predate interim policy on TB/HIV collaborative activities 4. Now that policy document exists, frequently asked question is: What will these activities cost?

  4. Objective To estimate the financial resources required for TB/HIV collaborative activities

  5. Methods - general • Defined the TB/HIV collaborative activities to be costed as the 12 activities recommended in WHO's interim policy document

  6. Methods - general • Which countries? 34 countries prioritized in "3 by 5" • Focus on health system (provider) costs • Focus on total annual costs; because detailed implementation plans not yet available for most countries, present 2 scenarios • First year of implementation, with ART limited to 10% HIV+ TB patients • Maximum levels of implementation, ART provided to all HIV+ TB patients ( ~350,000 people) • Estimate total annual costs by combining data on unit costs for each activity with estimates of annual numbers of people to whom activity relates. • Various estimates produced: present upper estimates

  7. Sources Unit cost data TB/HIV pilot projects in Malawi, Zambia, South Africa Cost analysis for "3 by 5" Numbers of people to whom activity relates TB notification data WHO estimates of number of HIV+ TB patients HIV prevalence data UN population estimates Futures group data on T+C Most important assumption ART costs only consider ART costs during period during which individual has TB and assume this is 6 months activity 12 defined as "ART for TB patients" Otherwise, cumulative cost effect large as costs will increase year on year Methods – sources and assumptions

  8. ART regimens • Standard first-line regimen : d4T/3TC/NVP, fixed-dose combination • US$140 low-income countries, US$304 elsewhere • TB patients: d4T/3TC/EFZ for 6 months • adds US$201 to fixed-dose first-line regimen • Female TB patients who are pregnant or at risk of pregnancy: ZDV/3TC/ABC for 6 months • adds US$527 to fixed-dose first-line regimen

  9. Annual costs by activity, US$ millions Scenario 1: Year 1, all start-up costs but limited ART Scenario 2: Full implementation, ART for all HIV+ TB patients Total = US$149 million ~ 35,000 HIV+ TB patients (10% total) enrolled on ART "3 by 5"assumed ~150,000 in 2004 Total = US$ 240 million ~ 350,000 TB patients enrolled on ART

  10. Annual costs by country (Scenario 2) South Africa (~ 2/3 is ART) Zimbabwe India Kenya Ethiopia Zambia 6 countries account for ~ 60% total costs ART unit costs used for S. Africa v. similar to national estimates (~ US$1200 p.a.)

  11. Key points to highlight 1. Limited data from which to produce estimates, especially • India and China • ART costs apart from the drugs themselves • Scaled up (vs. small scale) costs • Numbers that will access interventions in practice Important to collect more data as implementation proceeds 2. ART dominates costs, so is key cost to "get right" • Costs could be higher if Zambia consensus approach not followed • Costs to patients not included but may be important for health system to cover 3. Analysis of available funding and funding gaps is needed – e.g. through review of GFATM and PEPFAR proposals

  12. Conclusions 1. About US$250 million per year is needed for implementation of TB/HIV collaborative activities in the 34 countries that account for 90% of the global burden of HIV, and the biggest cost is ART 2. Figures are provisional but can be used for advocacy purposes 3. Estimates should be refined through: • Review of existing and future country plans and budgets for TB/HIV collaborative activities • Review of available funding • More analysis of both costs and numbers accessing interventions as activities are scaled up

  13. Acknowledgements Taghreed Adam Benjamin Johns John Stover Catherine Watt THD team

More Related